NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...

NEW YORK, May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a memb ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who purchased West common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements attributing issues to temporary COVID-related factors [5]. - The operational inefficiencies of the SmartDose device reportedly diluted profit margins, leading to potential restructuring activities and exit from key contracts [5].

Core Viewpoint - The Gross Law Firm is notifying shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that negatively impacted the company's financial performance during the specified class period [1][3]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services issued materially false and misleading statements regarding customer demand visibility and attributed operational challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with longstanding customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 16, 2023, to February 12, 2025, with a deadline for shareholders to register for the class action set for July 7, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, and there is no cost or obligation to participate [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices by companies [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2023, to February 12, 2025 [1]. Allegations - The complaint claims that West Pharmaceutical Services misrepresented its visibility into customer demand, attributing headwinds to temporary COVID-related product destocking while actually facing significant ongoing destocking in its high-margin HVP portfolio [1]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, negatively impacted the company's profit margins due to operational inefficiencies [1]. - The margin pressures are said to have created risks of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [1]. - As a result of these issues, the positive statements made by the defendants regarding the company's business, operations, and prospects were materially false or misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of WST during the specified timeframe are encouraged to register for the class action by July 7, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. About the Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by false or misleading statements that led to artificial inflation of stock prices [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - It is claimed that West's SmartDose device, intended as a high-margin growth product, has been dilutive to profit margins due to operational inefficiencies [4]. - The allegations include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [4]. Group 2: Financial Impact and Stock Performance - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following the announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [6]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][7]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding West's conduct [8].

Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP p ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking and operational inefficiencies that were not disclosed, leading to misleading positive statements about the company's prospects [5]. - The lawsuit asserts that these undisclosed issues resulted in damages to investors when the true situation became known [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, May 23, 2025 (GLOBE N ...

LOS ANGELES, May 22, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CLICK HERE BEFORE JULY 7, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.What Is The Lawsuit About? The complaint file ...